Kaan Boztug, Direktor des Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD), zugehöriger Forschungsgruppenleiter am CeMM Zentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften und Professor für Kinder und Jugendheilkunde an der Medizinischen Universität Wien und am St. Anna Kinderspital, erhält für seine Forschung an seltenen Erkrankungen den diesjährigen Clemens von Pirquet-Preis.
LBI-RUD members started today at the erste bank vienna night run thereby donating money to LICHT FÜR DIE WELT. The LBI-RUD is proud of its members and is highly supporting their activities in charity events.
Next a LBI-RUD team will start at the Krebsforschungslauf on October, 6th, raising money for cancer research.
From September 10-11, 2018 the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, in the person of Assoc. Prof. Kaan Boztug as Director of the LBI-RUD and head of ESID Working Party of Genetics, organized in cooperation with Marielle van Gijn (Head of Molecular Testing Working Group at ERN-RITA, a workshop on Human Phenotype Ontology (HPO) with a focus on immunodeficiencies and autoinflammatory diseases. HPO provides a standardized vocabulary to describe phenotypic (clinical) abnormalities observed in human diseases.
Call for Abstracts ends on September, 10th - Submit your abstract now
The Ludwig Boltzmann Gesellschaft invites interested scientists for this year’s LBG Meeting on Health Sciences from 29.-30. November 2018.
The meeting encourages and supports early career researchers to establish themselves within the scientific field. The conference focuses on the translation of research results from theory into practice. The thematic sessions will include keynote lectures by international experts and oral presentations of the best submitted abstracts.
LBI-RUD director Kaan Boztug, together with Loïc Dupré (LBI-RUD) and Jörg Menche (CeMM) won one out of five prestigious research grants by the Vienna Science and Technology Fund (WWTF) in their 2016 Life Science Precision Medicine Call, granted for their innovative research project that has the potential to significantly contribute to major advancements in the field of personalized medicine and treatment options. The funding amounts to a total of nearly 1 Mio. EUR for three years.